ExpreS2ion Biotech Holding AB (SE:EXPRS2)

:EXPRS2

EXPRS2

ExpreS2ion Biotech Holding AB

RESEARCH TOOLSreports

Want to see SE:EXPRS2 full AI Analyst Report?

ExpreS2ion Biotech Holding AB (EXPRS2) Price & Analysis

0 Followers

EXPRS2 Stock Chart & Stats

kr17.10

-kr1.20(-4.51%)

At close: Mar 06 4:00 PM EST

kr17.10

-kr1.20(-4.51%)

Day’s Range― - ―

52-Week Rangekr1.36 - kr12.22

Previous CloseN/A

Volume135.00

Average Volume (3M)19.88K

Market Cap

kr80.40M

Enterprise Value-kr39.53M

Total Cash (Recent Filing)kr47.55M

Total Debt (Recent Filing)kr2.21M

Price to Earnings (P/E)―

Beta1.39

Next Earnings

May 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.86

Shares Outstanding36,714,424

10 Day Avg. Volume26,629

30 Day Avg. Volume19,883

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)1.27

Price to Sales (P/S)12.37

P/FCF Ratio-1.11

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-9.64

Revenue Forecast (FY)kr10.00M

Bulls Say, Bears Say

Bulls Say

Proprietary Protein-expression PlatformExpreS2's proprietary insect-cell expression platform is a durable technical capability that allows production of complex antigens and VLP components. This creates a structural competitive advantage for service contracts and in-house vaccine programs, raising barriers to entry and supporting long-term customer relationships.

Platform/service And Partnership Revenue ModelA dual revenue model—service contracts for difficult-to-express proteins plus potential partnering and licensing payments—provides multiple durable monetization paths. Services can generate recurring contract revenue while partnerships offer milestone and royalty upside if development programs progress, diversifying cash sources.

Low Financial LeverageVery low debt levels reduce solvency and interest-rate risk and give management flexibility to fund operations or pursue partnerships. With modest leverage, the company has more optionality for bridge financings or strategic deals, which is important given biotech development timelines and episodic cash needs.

Bears Say

Persistent Operating LossesSustained operating and net losses indicate the core business has not yet achieved scalable profitability. Long-term loss-making undermines internal funding capacity, increases reliance on external capital, and risks dilution or constrained R&D/program investment if revenue generation does not meaningfully improve.

Consistent Negative Cash FlowPersistent negative operating and free cash flow show the company consumes cash rather than funds itself. Worsening FCF in 2025 heightens the need for external financing or partner funding, creating execution risk and potential interruptions to R&D or service capacity if financing terms deteriorate.

Contracting Equity/assets And Volatile RevenueMaterial contraction in equity/assets alongside small, volatile and recently declining revenue signals difficulty scaling the business and eroding financial resilience. This structural weakness raises governance and execution concerns and increases dependence on successful partnerships or fundraising to sustain operations.

EXPRS2 FAQ

What was ExpreS2ion Biotech Holding AB’s price range in the past 12 months?

ExpreS2ion Biotech Holding AB lowest stock price was kr1.36 and its highest was kr12.22 in the past 12 months.

What is ExpreS2ion Biotech Holding AB’s market cap?

ExpreS2ion Biotech Holding AB’s market cap is kr80.40M.

When is ExpreS2ion Biotech Holding AB’s upcoming earnings report date?

ExpreS2ion Biotech Holding AB’s upcoming earnings report date is May 28, 2026 which is in 27 days.

How were ExpreS2ion Biotech Holding AB’s earnings last quarter?

ExpreS2ion Biotech Holding AB released its earnings results on Feb 19, 2026. The company reported -kr0.859 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.859.

Is ExpreS2ion Biotech Holding AB overvalued?

According to Wall Street analysts ExpreS2ion Biotech Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ExpreS2ion Biotech Holding AB pay dividends?

ExpreS2ion Biotech Holding AB does not currently pay dividends.

What is ExpreS2ion Biotech Holding AB’s EPS estimate?

ExpreS2ion Biotech Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ExpreS2ion Biotech Holding AB have?

ExpreS2ion Biotech Holding AB has 36,714,424 shares outstanding.

What happened to ExpreS2ion Biotech Holding AB’s price movement after its last earnings report?

ExpreS2ion Biotech Holding AB reported an EPS of -kr0.859 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.283%.

Which hedge fund is a major shareholder of ExpreS2ion Biotech Holding AB?

Currently, no hedge funds are holding shares in SE:EXPRS2

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ExpreS2ion Biotech Holding AB

ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. ExpreS2ion Biotech Holding AB (publ) was founded in 2015 is based in Horsholm, Denmark.